Validation Study of the MDS Criteria for the Diagnosis of Multiple System Atrophy in the Mayo Clinic Brain Bank

被引:10
作者
Sekiya, Hiroaki [1 ,2 ]
Koga, Shunsuke [1 ]
Murakami, Aya [1 ,3 ]
Kawazoe, Miki [1 ,4 ]
Kim, Minji
Martin, Nicholas B. [1 ]
Uitti, Ryan J. [5 ]
Cheshire, William P.
Wszolek, Zbigniew K.
Dickson, Dennis W. [1 ]
机构
[1] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA
[2] Kobe Univ, Grad Sch Med, Div Neurol, Hyogo, Japan
[3] Kansai Med Univ, Dept Neurol, Hirakata, Japan
[4] Mayo Clin, Dept Artificial Intelligence & Informat Res, Jacksonville, FL USA
[5] Mayo Clin, Dept Neurol, Jacksonville, FL USA
基金
美国国家卫生研究院;
关键词
OLIVOPONTOCEREBELLAR ATROPHY; COGNITIVE IMPAIRMENT; NATURAL-HISTORY; AUTOPSY; MSA; STATEMENT; PATHOLOGY; SPECTRUM; PSP;
D O I
10.1212/WNL.0000000000207905
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and ObjectiveThe second consensus criteria in 2008 have been used in diagnosing multiple system atrophy (MSA). The International Parkinson and Movement Disorder Society (MDS) proposed new diagnostic criteria for MSA in 2022. This study aimed to compare the diagnostic accuracy between these 2 criteria and validate the clinical utility of the newly proposed criteria for MSA.MethodsWe conducted a retrospective autopsy cohort study of consecutive patients with a clinical or pathologic diagnosis of MSA from the Mayo Clinic brain bank between 1998 and 2021. We studied 352 patients (250 pathologically diagnosed MSA and 102 non-MSA); MDS criteria and the second consensus criteria were applied. The sensitivity, specificity, and area under the curve (AUC) of receiver operating characteristic curves were compared between these criteria. Comparison was conducted between clinical subtypes and among clinically challenging cases (those with different clinical diagnoses or those with suspected but undiagnosed MSA before death). We also used machine learning algorithm, eXtreme Gradient Boosting, to identify clinical features contributing diagnostic performance.ResultsThe sensitivity and specificity of clinically established and probable MSA by the MDS criteria were 16% and 99% and 64% and 74%, respectively. The sensitivity and specificity of probable MSA and possible MSA by the second consensus criteria were 72% and 52% and 93% and 21%, respectively. The AUC of MDS clinically probable MSA was the highest (0.69). The diagnostic performance did not differ between clinical subtypes. In clinically challenging cases, MDS clinically established MSA maintained high specificity and MDS clinically probable MSA demonstrated the highest AUC (0.62). MRI findings contributed to high specificity. In addition, combining core clinical features with 2 or more from any of the 13 supporting features and the absence of exclusion criteria also yielded high specificity. Among supporting features, rapid progression was most important for predicting MSA pathology.DiscussionThe MDS criteria showed high specificity with clinically established MSA and moderate sensitivity and specificity with clinically probable MSA. The observation that high specificity could be achieved with clinical features alone suggests that MSA diagnosis with high specificity is possible even in areas where MRI is not readily available.
引用
收藏
页码:E2460 / E2471
页数:12
相关论文
共 39 条
  • [1] Clinical diagnosis sensitivity of neuropathologically established multiple system atrophy in Japan
    Ando, Takashi
    Riku, Yuichi
    Akagi, Akio
    Miyahara, Hiroaki
    Sone, Jun
    Katsuno, Masahisa
    Yoshida, Mari
    Iwasaki, Yasushi
    [J]. JOURNAL OF NEUROLOGY, 2022, 269 (09) : 5162 - 5164
  • [2] α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies The Way Forward
    Bellomo, Giovanni
    De Luca, Chiara Maria Giulia
    Paoletti, Federico Paolini
    Gaetani, Lorenzo
    Moda, Fabio
    Parnetti, Lucilla
    [J]. NEUROLOGY, 2022, 99 (05) : 195 - 205
  • [3] XGBoost: A Scalable Tree Boosting System
    Chen, Tianqi
    Guestrin, Carlos
    [J]. KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, 2016, : 785 - 794
  • [4] Expanding the spectrum of neuronal pathology in multiple system atrophy
    Cykowski, Matthew D.
    Coon, Elizabeth A.
    Powell, Suzanne Z.
    Jenkins, Sarah M.
    Benarroch, Eduardo E.
    Low, Phillip A.
    Schmeichel, Ann M.
    Parisi, Joseph E.
    [J]. BRAIN, 2015, 138 : 2293 - 2309
  • [5] Multiple-System Atrophy
    Fanciulli, Alessandra
    Wenning, Gregor K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (03) : 249 - 263
  • [6] Cutaneous a-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
    Gibbons, Christopher
    Wang, Ningshan
    Rajan, Sharika
    Kern, Drew
    Palma, Jose-Alberto
    Kaufmann, Horacio
    Freeman, Roy
    [J]. NEUROLOGY, 2023, 100 (15) : E1529 - E1539
  • [7] Second consensus statement on the diagnosis of multiple system atrophy
    Gilman, S.
    Wenning, G. K.
    Low, P. A.
    Brooks, D. J.
    Mathias, C. J.
    Trojanowski, J. Q.
    Wood, N. W.
    Colosimo, C.
    Duerr, A.
    Fowler, C. J.
    Kaufmann, H.
    Klockgether, T.
    Lees, A.
    Poewe, W.
    Quinn, N.
    Revesz, T.
    Robertson, D.
    Sandroni, P.
    Seppi, K.
    Vidailhet, M.
    [J]. NEUROLOGY, 2008, 71 (09) : 670 - 676
  • [8] Autonomic Dysfunction in α-Synucleinopathies
    Javier Mendoza-Velasquez, Jose
    Francisco Flores-Vazquez, Juan
    Barron-Velazquez, Evalinda
    Luisa Sosa-Ortiz, Ana
    Illigens, Ben-Min Woo
    Siepmann, Timo
    [J]. FRONTIERS IN NEUROLOGY, 2019, 10
  • [9] Assessment of dementia in patients with multiple system atrophy
    Kitayama, M.
    Wada-Isoe, K.
    Irizawa, Y.
    Nakashima, K.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (05) : 589 - 594
  • [10] Neuropathology and molecular diagnosis of Synucleinopathies
    Koga, Shunsuke
    Sekiya, Hiroaki
    Kondru, Naveen
    Ross, Owen A.
    Dickson, Dennis W.
    [J]. MOLECULAR NEURODEGENERATION, 2021, 16 (01)